Abstract
Cardiac failure is a clinical entity of various causes and severity characterized by an inability of the heart to deliver a sufficient amount of blood to meet the metabolic demands of the body at rest or during exercise. Thus, as acute or chronic heart failure develops, several compensatory mechanisms are activated to maintain an adequate perfusion to vital organs such as the brain and the heart, at the expense of other non-essential organs such as the kidneys, the gut or the muscles. The neurohumoral systems involved in the maintenance of blood pressure when heart function is failing are the same as those implicated in the regulation of blood pressure when dehydration or severe losses of blood volume occur i.e. the sympathetic nervous system, the renin-angiotensin-aldosterone system and plasma arginine vasopressin. This endocrine response results in various degrees of peripheral vasoconstriction and renal sodium retention depending on the severity of the cardiocirculatory imbalance. In advanced heart failure, however, the increase in peripheral resistance and the enhanced sodium reabsorption with subsequent volume expansion are likely to compromise myocardial function by increasing afterload as well as myocardial oxygen consumption. A vicious circle is established that will lead to further irreversible myocardial damage despite the activation of other systems with vasodilatory and natriuretic properties such as the atrial natriuretic peptide or the protaglandins. An integrated scheme demonstrating the neurohumoral consequences of heart failure is presented in Fig. 1.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Di Bona GF (1977) Neurogenic regulation of renal tubular sodium reabsorption. Am J Physiol 233: 173–181
Goldstein DS, McCarthy R, Polinsky RJ, Kopin IJ (1983) Relationship between plasma norepinephrine and sympathetic neural activity. Hypertension 5: 552–559
Thomas JA, Marks BH (1978) Plasma norepinephrine in congestive heart failure. Am J Cardiol 41: 233–243
Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN (1982) Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49: 1659–1666
Gaffney TE, Braunwald E (1963) Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 34: 320–324
Cohn JN, Levine TB, Olivari MT, et al (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823
Chidsey CA, Braunwald E, Morrow AG (1965) Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 39: 442–450
Dzau VJ, Hollenberg NK, Williams GH (1983) Neurohumoral mechanisms of heart failure: role in pathogenesis, therapy, and drug tolerance. Fed Proc 42: 3162–3169
Bristow MR, Ginsburg R, Monibe W, et al (1982) Decreased catecholamine sensitivity and 1-adrenergic-receptor density in failing human heart. N Engl J Med 307: 205–211
Chidsey CA, Braunwald E, Morrow AG, Mason DT (1963) Myocardial norepinephrine concentration in man: Effects of reserpine and of congestive heart failure. N Engl J Med 269: 653–658
Pierpont GL, Francis GS, DeMaster EG, Levine TB, Bolman RM, Cohn JN (1983) Elevated left ventricular myocardial dopamine in preterminal idiopathic dilated cardiomyopathy. Am J Cardiol 52: 1033–1035
Chidsey CA, Harrison OL, Braunwald E (1962) Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 267: 650–654
Olivari MT, Levine TB, Cohn JN (1983) Abnormal neurohumoral response to nitroprusside infusion in congestive heart failure. J Am Coll Cardiol 2 (3): 411–417
Eckberg DL, Drabinsky M, Braunwald E (1971) Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 285: 877–883
Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dillenkoffer RL (1981) Short-term effects of intravenous clonidine in congestive heart failure. Clin Pharmacol Ther 30: 724–728
Francis GS, Parks R, Cohn JN (1983) The effects of bromocriptin in patient with congestive heart failure. Am Heart J 106: 100–106
Levine TB (1985) Role of vasodilators in the treatment of congestive heart failure. Am J Cardiol 55: 32A - 35A
Elkayam U, Le Jemtel TH, Mathur M, et al (1979) Marked early attenuation of hemodynamic effect of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol 44: 540–545
Veterans Administration Cooperative Study (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 314: 1547–1552
Colucci WS, Williams GH, Braunwald E (1981) Clinical, hemodynamic and neuroendocrine effects of chronic prazosin therapy for congestive heart failure. Am Heart J 102: 615–621
Goldberg LI, Hsieh YY, Resnetov L (1977) Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Progr Cardiovasc Dis 19 (4): 327–340
Colucci WS, Alexander RW, Williams GH, et al (1981) Decreased lymphocyte ß-adrenergicreceptor density in patients with heart failure and tolerance to the ß-adrenergic agonist pirbuterol. N Engl J Med 305: 185–190
Rajfer SI, Anton AH, Rossen JD, Goldberg LI (1984) Beneficial hemodynamic effects of oral levodopa in heart failure. N Engl J Med 310: 1357–1362
Fisher ML, Plotnick GD, Peters RW, Carliner NH (1986) Beta-blockers in congestive cardiomypathy. Conceptual advance or contraindication. Am J Med 80 (Suppl 2B): 59–66
Packer M (1987) Converting enzyme inhibition in the management of severe chronic congestive heart failure: physiologic concepts. J Cardiovasc Pharmacol 10 (S7): S83 - S87
Deboben A, Inagami T, Ganten D (1983) Tissue renin. In: Genest J, Kuchel O, Hamet P, Cantin M (eds) Hypertension–physiopathology and treatment. McGraw-Hill, New York, pp 194–209
Gavras H, Kremer D, Brown JJ, et al (1975) Angiotensin-and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J 89 (3): 321–332
Turini GA, Brunner HR (1982) The role of hormones in congestive heart failure: new frontiers in therapy? Clin Sci 63: 333–338
Turini GA, Waeber B, Brunner HR (1983) The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captropril and enalapril. Eur Heart J 4 (Suppl A): 189–197
Captopril Multicenter Research Group (1983) A pacebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2: 755–763
The Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 23: 1429–1435
Fyhrquist F, Hortling L, Forslund T, Laasonen L (1982) Reduction of plasma vasopressin and renin substrate in congestive heart failure during captopril treatment. From principle to practice, Biomedical Information Co, New York pp 51–62
Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet DG, Berl T, Schrier RW (1981) Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305: 263–266
Bichet DG, Kortas C, Mettauer B, et al (1986) Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int 29: 1188–1196
Montani JP, Liard JF, Schoun J, Moehring JH (1980) Hemodynamic effect of exogenous and endogenous vasopressin at low concentrations in conscious dogs. Circ Res 47: 346–355
Cowley AW, Monos E, Guyton AC (1974) Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 34: 505–514
Goldsmith SR, Francis GS, Cowley AW, Goldenberg IF, Cohn JN (1986) Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 8: 779–783
Nicod P, Biollaz J, Waeber B, et al (1986) Hormonal, global and regional hemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatremia. Br Heart J 56: 433–439
Edwards BS, Zimmerman RS, Burnett JC (1987) Atrial natriuretic factor: physiologic actions and implications in congestive heart failure. Cardiovasc Drugs Ther 1: 89–100
Biollaz J, Bidiville J, Diézi J, et al (1987) Site of the action of a synthetic atrial natriuretic peptide evaluated in humans. Kidney Int 32: 537–546
Cody RJ, Atlas SA, Laragh JH, et al (1986) Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal and hemodynamic responses to peptide infusion. J Clin Invest 78: 1362–1374
Goy JJ, Waeber B, Nussberger J, et al (1988) Infusion of atrial natriuretic peptide to patients with congestive heart failure. J Cardiovasc Pharmacol (In press)
Tsunoda K, Mandelsohn FAO, Sexton PM, Chai SY, Hodsman GP, Johnston CI (1988) Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure. Circ Res 62: 155–161
Mauer EF (1955) The toxic effects of phenylbutazone (butazolidin): review of the literature and report of the twenty-third death following its use. N Engl J Med 253: 404–410
Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH (1984) Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 310: 347–352
Liang CS, Imai N, Stone CK, Woolf PD, Kawashima S, Tuttle RR (1987) The role of endogenous opioids in congestive heart failure: effects of nalamefene on systemic and regional hemodynamic in dogs. Circulation 75 (2): 443–451
Archelos J, Xiang JZ, Lang RE (1987) Regulation of release and function of neuropeptides in the heart. J Cardiovasc Pharmacol 10 (Suppl 12): S45 - S50
Waeber B, Aubert JF, Corder R, et al (1988) Cardiovascular effects of neuropeptide Y. Am J Hypertension (In press)
Lee WH, Packer M (1986) Congestive heart failure: Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation 73: 257–267
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Burnier, M., Waeber, B., Nussberger, J., Brunner, H.R. (1988). Endocrine Response to Heart Failure. In: Perret, C., Vincent, J.L. (eds) Acute Heart Failure. Update in Intensive Care and Emergency Medicine, vol 6. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83453-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-83453-0_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19169-8
Online ISBN: 978-3-642-83453-0
eBook Packages: Springer Book Archive